Insight Capital Research & Management’s iShares Biotechnology ETF IBB Stock Holding History

Insight Capital Research & Management’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-3,045	Closed	-$269K	–	94
2016 Q4	$269K	Hold	3,045	–	–	0.14%	104
2016 Q3	$294K	Hold	3,045	–	–	0.13%	93
2016 Q2	$261K	Hold	3,045	–	–	0.09%	96
2016 Q1	$265K	Sell	3,045 -1,245	-29%	-$111K	0.08%	91
2015 Q4	$484K	Buy	4,290 +360	+9%	+$39.1K	0.14%	90
2015 Q3	$397K	Hold	3,930	–	–	0.12%	84
2015 Q2	$483K	Hold	3,930	–	–	0.13%	93
2015 Q1	$450K	Hold	3,930	–	–	0.11%	108
2014 Q4	$397K	Hold	3,930	–	–	0.1%	119
2014 Q3	$358K	Buy	+3,930	New	+$345K	0.09%	109

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Insight Capital Research & Management's IBB Position: Q1 2017 in Review

Insight Capital Research & Management sold out of iShares Biotechnology ETF (IBB) in Q1 2017, closing a stake of 3,045 shares — an estimated $269K sold.

Insight Capital Research & Management first reported a position in IBB in Q3 2014 and held it in 10 quarters. The position peaked at $484K in Q4 2015. 521 funds tracked by Wall St. Rank hold IBB as of Q1 2017.

Insight Capital Research & Management reported no remaining iShares Biotechnology ETF position as of Q1 2017 after selling out during the quarter.
Insight Capital Research & Management sold 3,045 iShares Biotechnology ETF shares in Q1 2017, an estimated $269K.
Insight Capital Research & Management first reported a position in iShares Biotechnology ETF in Q3 2014 and held it in 10 quarters.
Insight Capital Research & Management's iShares Biotechnology ETF position peaked at $484K in Q4 2015.
521 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2017.

Based on Insight Capital Research & Management's 13F filing for Q1 2017, filed 8 May 2017.